Pathway

Calms inflammation

NF-κB↓

The Immune Alarm

39 blends on this site modulate it.

Also searched as NF-κB.

But read the nuance, because it is the whole story: the balance here is about duration, not destination. Acute nf-κB is how you defend yourself and how a damaged liver regenerates; it is the smouldering, never-resolving version that drives insulin resistance, muscle loss, a leaky gut barrier, joint degradation, atherosclerosis and the low fire beneath aging. Nobody needs to raise this. It is raised for you by injury, infection, visceral fat and poor sleep.

In depth

The master inflammatory switch — indispensable to defend against threat, corrosive when it never stands down.

What drives it

Builds mitochondria reduces it.

PGC-1α inhibits NF-κB, a master activator of proinflammatory gene expression, and additionally activates PPAR-α/γ which mediate anti-inflammatory effects (PMC8321869) — the mechanistic link from mitochondrial biogenesis to lower inflammatory tone. And the source states something stronger than this arrow: PGC-1-alpha and NF-kappa-B ARE reciprocally regulated, and the loop is vicious. During inflammation NF-kappa-B reduces PGC-1-alpha expression and activity; low PGC-1-alpha then downregulates antioxidant target genes, producing oxidative stress; and low PGC-1-alpha with that oxidative stress promotes NF-kappa-B activity, exacerbating the inflammatory response. PMC8321869

Growth factor reduces it.

IGF-1/Akt signaling inhibits the atrophy-inducing NF-κB and Smad/myostatin pathways in skeletal muscle (PMC7564605) — IGF-1 is anti-catabolic as well as anabolic. the review states the role of IGF-1 in atrophy specifically is less clear than its hypertrophy role, and IGF-1/PI3K/Akt signaling falls during denervation, unloading and immobilization -- so the protective arm is itself lost in the conditions where it is most needed. PMC7564605

Oxidative stress increases it.

Schreck, Rieber & Baeuerle 1991, EMBO J 10:2247 — reactive oxygen intermediates are common messengers activating NF-κB. PMID 2065663. ROS is dose-dependent: physiological ROS signals, excess ROS damages. 'Lower ROS' is therefore not universally desirable. Verified: oxidants activate the transcription factors Nrf2, HIF-1-alpha, AP-1, NF-kappa-B, FoxO and p53. NF-kB, p53 and HIF-1-alpha are additionally regulated by the redox factor Ref-1 under thioredoxin control. Verbatim: “NOX2, predominantly expressed in immune cells, produces ·O2− that activate the NF-κB signaling pathway, inducing pro-inflammatory cytokines like IL-6 and TNF-α, exacerbating acute inflammation, and damaging the mucosal barrier”. doi 10.1080/13510002.2025.2458942 · PMID 2065663 · PMC11792148

Innate immune sensor increases it.

How the body first notices — and why noticing is not harmless. 'release of PAMPs and DAMPs activates innate immune pathways' (Heart Failure Reviews 2026, doi 10.1007/s10741-026-10654-y), which run through the same master inflammatory switch that drives the inflammatory response. ⇒ the alarm that detects the virus is the same alarm that, left on, damages the muscle. That is why the second phase is the dangerous one. doi 10.1007/s10741-026-10654-y

Antioxidant defense reduces it.

Kobayashi 2016, Nat Commun 7:11624 — Nrf2 binds proinflammatory promoters and blocks Pol II, suppressing NF-κB cytokines. doi 10.1038/ncomms11624

Longevity gene reduces it.

Yeung 2004, EMBO J 23:2369 — SIRT1 deacetylates RelA/p65 at Lys310, inhibiting NF-κB transcription. PMID 15152190. Mechanism: SIRT1 is the primary deacetylase of the NF-kappa-B p65 subunit at lysine 310. Bidirectional evidence, which is rare and strong: SIRT1 overexpression attenuated TNF-alpha-induced p65 acetylation, while SIRT1 inhibition by EX-527 increased it. Small-molecule SIRT1 activators suppressed TNF-alpha-induced NF-kappa-B transcriptional activation and reduced LPS-stimulated TNF-alpha secretion in A SIRT1-dependent manner, and in an acute mouse LPS model the STAC SRTCX1003 decreased TNF-alpha and IL-12 production in vivo. Additional routes: SIRT1 inhibits IkB degradation, and resveratrol blocks nuclear aggregation of p65 and its DNA binding. SIRT1 suppresses NF-kappa-B activity while NF-kappa-B induces SIRT1 expression: a negative feedback loop. PMID 15152190

H. pylori increases it.

The damage is inflammatory and it does not stop at the stomach lining: chronic H. pylori gastritis drives gastric atrophy and, through the resulting achlorhydria, a dysbiotic gastric microbiome that carries the process toward neoplasia (PMC11558793). In a pivotal trial, eradication after endoscopic removal of early gastric cancer reduced metachronous gastric cancer versus placebo; in an earlier cohort, no second cancer occurred in the eradicated group against 9% in the non-eradicated group over five years. PMC11558793

Gum pockets and attachment increases it.

Gum inflammation does not stay in the mouth, and treating it lowers a systemic marker: a systematic review and meta-analysis of 26 randomized controlled trials in 2,579 participants found that treating periodontitis reduced C-reactive protein by 0.69 mg/L (95% CI −0.97 to −0.40) at six months (PMC10087558). Recurrent bacteremia with periodontal pathogens can damage vascular endothelium, and the landmark trial of intensive periodontal therapy improved brachial-artery endothelial function (Tonetti et al., N Engl J Med 2007;356:911). PMC10087558

Clears worn-out cells increases it.

Reverse ARROWTHE forward edge's own source proves it: Chien 2011, Genes Dev 25:2125 identified the NF-kappa-B subunit p65 as a major transcription factor that accumulates on the chromatin of senescent cells, acting as master regulator of the SASP and influencing more genes than RB and p53 combined. Corroborated independently: paracrine senescence of mesenchymal stromal cells involves inflammatory cytokines and the NF-kappa-B pathway (Cells 2022;11:3324); the SASP factor IL-6 sustains senescence through cytosolic DNA, cGAS-STING and NF-kappa-B activation (PMC11464112); and by activating the DNA-damage response in bystander cells the SASP spreads senescence to neighbors. Scope, and it is not universal: secondary oncogene-induced senescence requires notch, rather than SASP alone as previously thought (PMC6486482); and centrosome-amplification SASP is non-canonical and lacks prominent NF-kappa-B activation (PMC10014068). Gates 2-5 cleared before the edge was drawn. PMC11464112

Senescent cell signaling increases it.

NF-kB acts as a master regulator of the SASP, influencing the expression of more genes than RB and p53 combined. doi 10.1016/j.cellsig.2011.12.006 · PMID 21979375 · PMC7767554

Pathogen tripwire increases it.

Verbatim: 'We identified two axes of response: an NF-kB-dependent response similarly elicited by all Mtb pathogen-associated molecular patterns (PAMPs) and a type I interferon axis unique to cells infected with live Mtb.' (10.1128/msystems.00052-23). What was measured: Bulk and single-cell macrophage transcriptional response partitioned into an NF-kB-dependent module versus a type I interferon module, after exposure to purified Mtb-derived molecules. doi 10.1128/msystems.00052-23

Cell fate signaling reduces it.

Human Notch-1 inhibits NF-kappa B activity in the nucleus through a direct interaction involving a novel domain. 10.1038/labinvest.3700700. doi 10.1038/labinvest.3700700

Immunotherapy heart inflammation increases it.

The same self-antigen, reached by a completely different road. 'Mechanistic studies further implicate autoreactive T cells targeting cardiac α-MYOSIN heavy chain (α-MyHC), a contractile protein uniquely expressed in cardiac muscle, as central mediators... In preclinical models, immunization with α-MyHC peptides induces autoimmune myocarditis' (pmc12698404 · doi 10.3389/fimmu.2025.1677984 — Overview of immune checkpoint inhibitor associated myocarditis mechanisms diagnostics and treatment). ⇒ this is the exact protein used to create the laboratory autoimmune model. A virus can expose it, a cancer drug can unmask it, and a syringe can inject it — and the heart suffers the same way in all three cases. The downstream is shared too: 'dual blockade of PD-1 and CTLA-4 induces a pro-inflammatory phenotype in cardiac tissues through upregulation of NF-κB, NLRP3 inflammasome components, and MyD88'. doi 10.3389/fimmu.2025.1677984

Heavy metal burden increases it.

doi 10.1007/s12291-025-01354-9: heavy metals induce overproduction of ROS and RNS which overwhelm antioxidant defenses, and this disruption of cellular homeostasis 'activates inflammatory pathways, including the NLRP3 inflammasome and redox-sensitive transcription factors like NF-kB, leading to the release of pro-inflammatory cytokines such as TNF-alpha and IL-6.' Corroborated by doi 10.3390/metabo16050319: toxic metals 'disrupt redox homeostasis, impair cellular integrity, and activate inflammatory signaling pathways.'. Verbatim from the source for this edge — doi 10.1007/s12291-025-01354-9. doi 10.1007/s12291-025-01354-9:

What it drives

It increases Ceramide load.

Holland/Summers 2011, J Clin Invest - the TLR4 signal reaches the ceramide enzymes through NF-kappa-B. Verbatim: This transcriptional regulation is governed by NF-kappaB, as the loss of IkappaKbeta, an upstream kinase involved in NF-kappaB activation, blocks the response. Accordingly, treatment of diet-induced-obese mice with the IkappaK inhibitor sodium salicylate selectively reduced tissue ceramides and restored insulin sensitivity. Shown in mice. This edge is why anti-inflammatory ingredients can lower ceramide at all - they act on the switch, not on the lipid. doi 10.1172/JCI57144

It reduces Muscle.

NF-κB activation is sufficient to induce skeletal-muscle atrophy: cachectic cytokines such as TNF-α drive NF-κB, which up-regulates the E3 ubiquitin ligase MuRF1 and accelerates ubiquitin-proteasome protein degradation (PMC7564605). This is the inflammatory route to sarcopenia. Mouse atrophy models (denervation, dexamethasone, fasting, cancer cachexia, aging) plus C2C12 myotubes treated with dexamethasone, TNF-alpha and H2O2. PMC7564605

It reduces Insulin sensitivity.

Hotamisligil 1993, Science 259:87 — adipose TNF-α (an NF-κB-driven inflammatory cytokine) blocks insulin action; neutralizing TNF-α restores insulin-stimulated glucose uptake. doi:10.1126/science.7678183. The demonstration is loss-of-function and that is its strength: TNF-alpha mRNA was induced in adipose tissue across four different rodent obesity/diabetes models, protein rose locally and systemically, and neutralizing TNF-alpha in obese fa/fa rats caused a significant increase in peripheral glucose uptake in response to insulin. Species — the landmark paper is entirely rodent. The human counterpart is a separate, later study (Hotamisligil 1995, PMID 7738205): adipose TNF-alpha mRNA in 18 control vs 19 obese premenopausal women, and that paper states plainly that the mechanisms linking obesity to insulin resistance and diabetes in humans remain largely unknown. And the review found disconfirming human evidence that must travel with this edge: subcutaneous adipose tissue was shown to release interleukin-6 but not TNF-alpha in vivo in humans (Mohamed-Ali 1997, J Clin Endocrinol Metab 82:4196-4200). If adipose TNF-alpha is not exported systemically in people, its action is LOCAL/PARACRINE and the systemic rodent story does not transfer intact. The edge stands on the rodent loss-of-function; the human systemic route is contested. doi 10.1126/science.7678183. · PMID 7738205

It increases Tissue renewal.

NF-κB/liver-regeneration review 2010 — NF-κB activation (in Kupffer cells) drives the priming phase of liver regeneration via sequential TNF-α/IL-6 production, licensing hepatocyte proliferation. PMC2948885. The claim as drawn: a pro-inflammatory response mediated predominantly through Kupffer cells primes hepatocytes to enter the cell cycle during the 0-6h priming phase after partial hepatectomy, and transient upregulation of NF-kappa-B and JNK in TLR/MyD88 and TNFR signaling leads to normal regeneration (PMC2948885; PMC4493398). But hepatocyte NF-kappa-B is not the one that matters: attenuating NF-kappa-B in ~45% of hepatocytes with an IkB-alpha superrepressor did not alter regeneration, and hepatocyte-specific IKK-beta deletion did not alter PH-induced proliferation — yet inactivating IKK-beta in all liver cells including Kupffer cells did impair it. The stated conclusion is that NF-kappa-B signaling within hepatocytes is irrelevant to the regenerative response and instead fulfils a cytoprotective role; the regenerative signal comes from non-parenchymal cells (PMC3462179). And the canonical subunit is dispensable — a paper is titled 'the NF-kappa-B subunit RelA/p65 is dispensable for successful liver regeneration after partial hepatectomy in mice'. And the noncanonical arm runs the other way: hepatic NIK (NF-kappa-B-inducing kinase) and its substrate IKK-alpha suppress reparative hepatocyte proliferation, at least partly by inhibiting JAK2/STAT3, and are aberrantly activated in chronic liver disease (eLife 2018;7:e34152). So within one node: canonical NF-kappa-B in Kupffer cells promotes regeneration, hepatocyte NF-kappa-B is cytoprotective not proliferative, and the noncanonical NIK/IKK-alpha branch blocks regeneration. 'Lower NF-kappa-B' has no single meaning here at all. PMC2948885

It reduces Clot breakdown.

Swiatkowska 2005 — TNF-α/ROS induces PAI-1 (the primary inhibitor of fibrinolysis) via NF-κB binding the PAI-1 promoter; a super-suppressor IκBα abolishes it. PMID 16279946

It reduces Gut barrier.

NF-κB/tight-junction study 2021, PLoS One — NF-κB activation induces myosin light-chain kinase (MLCK), increasing intestinal epithelial tight-junction permeability and disrupting the barrier. doi:10.1371/journal.pone.0249544. The mechanism is specific, not generic inflammation: barrier loss runs through NF-kappa-B p65 nuclear translocation driving myosin light chain kinase (MLCK) gene and protein expression, plus post-transcriptional modulation of occludin by microRNA. Loss-of-function is decisive here: knocking down NF-kappa-B p65 by siRNA prevented the MMP-9-induced IL-8 expression, prevented the MLCK protein increase, and prevented the rise in tight-junction permeability. A cell-type reversal worth knowing before any probiotic claim: Lactobacillus acidophilus prevented TNF-alpha-induced permeability by inhibiting NF-kappa-B p50/p65 and MLCK in intestinal cells (TLR-2-dependent, MyD88-INdependent) — while the same organism activated NF-kappa-B p50/p65 in immune cells (TLR-2- and MyD88-dependent). One probiotic, opposite effects on the same transcription factor, decided by cell type. 'Lowers NF-kappa-B' is not a coherent whole-body claim. Caco-2 monolayers in vitro plus animal models; the human cytokines shown to drive this route are IL-1-beta, TNF-alpha and IFN-gamma, in IBD (Crohn's, ulcerative colitis, necrotising enterocolitis, coeliac). doi 10.1371/journal.pone.0249544.

It increases Cell fate signaling.

NF-κB/Notch1 study 2017, Sci Rep — NF-κB-dependent activation of the Notch1 gene (and induction of its ligand Jagged1) drives Notch signaling in inflamed tissue. doi 10.1038/s41598-017-06750-7

It reduces Hair.

NF-κB-driven perifollicular microinflammation is an established feature of androgenetic alopecia: the chronic low-grade infiltrate secretes cytokines that shorten anagen and drive follicle miniaturization. doi 10.2147/DDDT.S542000

It reduces Joint comfort.

NF-κB-in-OA review 2019, Cells — NF-κB signaling drives chondrocyte catabolism (MMPs/ADAMTS) and suppresses cartilage anabolism, degrading joint cartilage and impairing joint function. doi:10.3390/cells8070734. Joint function falls by the same route: NF-kappa-B-driven chondrocyte catabolism raises MMP-13 and ADAMTS-5, degrading aggrecan and COL2A1 while lowering Bcl-2 and raising cleaved caspase-3 and BAX. demonstrated in IL-1-beta-stimulated chondrocytes and DMM-induced OA mice, plus bovine and human chondrocyte culture -- these are induced models of joint damage, not normal joint physiology. doi 10.3390/cells8070734.

It increases Inflammatory alarm.

Bauernfeind 2009, J Immunol 183:787 — NF-κB licenses NLRP3 by inducing its expression (priming step). PMID 19570822. The word 'license' is doing precise work and the atlas should not blur it: NLRP3 has a two-signal requirement. NF-kappa-B supplies signal 1 only — priming, i.e. transcriptional induction of NLRP3, pro-IL-1-beta and pro-IL-18 downstream of TLR4 or TNF receptor signaling. Signal 2, the actual assembly, requires a separate stimulus: PAMPs and DAMPs including extracellular ATP, pore-forming toxins, RNA viruses and particulate matter (PMC8093260). NF-kappa-B makes the inflammasome possible; it does not fire it. Necessary, not sufficient. And transcriptional priming is not the only route: NLRP3 can be primed non-transcriptionally by a short LPS pulse via phosphorylation, de-phosphorylation, de-ubiquitination and de-sumoylation; transgenic NLRP3 expression bypasses the transcriptional priming requirement entirely — which confirms NF-kappa-B's contribution is at the level of expression, not activation. Species: the NEK7-dependence work is mainly murine; human myeloid cells were shown to activate NLRP3 by a NEK7-independent route. PMID 19570822 · PMC8093260

It increases Clears worn-out cells.

Chien 2011, Genes Dev 25:2125 — NF-κB is the master SASP regulator, reinforcing the senescence arrest. PMID 21979375. NF-kappa-B is named a central driver of the SASP program, linking intracellular stress to sustained inflammatory output; in chondrocytes the p38 MAPK/NF-kappa-B axis promotes senescence under oxidative stress and mechanical overload specifically. An UNMAPPED reverse arrow, and the source calls it a loop: SASP factors released by senescent chondrocytes and stromal cells reinforce NF-kappa-B activation in neighboring cells, propagating matrix catabolism and secondary senescence across the joint. The authors describe a self-reinforcing feed-forward loop -- NF-kappa-B drives SASP, SASP sustains NF-kappa-B. PMID 21979375

It increases Brain inflammation.

Anilkumar & Wright-Jin 2024, Cells 13:485 — microglial NF-κB upregulates proinflammatory genes, driving neuroinflammation. PMID 38534329. Mechanism: microglia, the primary immune responders of the CNS, upregulate NF-kappa-B on activation in pathological conditions; NF-kappa-B activation drives proinflammatory functional change and release of cytokines and chemokines that act on other CNS cells, and microglial crosstalk can then induce cell death, exacerbating pathology. Loss-of-function, stated plainly by the authors: microglia-specific NF-kappa-B inhibition is typically associated with positive downstream results. Independently, microglia-specific deletion of NIK (noncanonical NF-kappa-B) had NO effect on EAE disease onset but attenuated disease progression (Cell Mol Immunol 2025, doi 10.1038/s41423-025-01310-w) — the pathway matters for progression, not initiation. The authors close by noting that the diverse effect of NF-kappa-B across CNS cell types requires further investigation before this pathway can be manipulated therapeutically. 'Lowering NF-kappa-B' remains an incoherent whole-body instruction; the compartment decides. doi 10.1038/s41423-025-01310-w · PMID 38534329

It increases Arterial plaque.

Atherosclerosis is a chronic inflammatory disorder, not only lipid deposition. CANTOS proved it causally: canakinumab, which neutralizes IL-1β downstream of NF-κB/NLRP3, significantly reduced recurrent cardiovascular events in prior-MI patients independent of any lipid lowering (PMC5857062; mechanism review PMC11989677). Note: the same trial showed no effect on cardiovascular or all-cause mortality and a higher rate of fatal infection — it establishes the pathway, not a treatment. Mechanism at the initiating step: NF-kappa-B drives endothelial expression of the leukocyte adhesion molecules E-selectin, VCAM-1 and ICAM-1, plus the chemokines MCP-1, IL-8 and CCL20 — which recruit circulating monocytes into the arterial intima. Loss-of-function: inhibiting NF-kappa-B with a super-repressor IkB-alpha blunted all signs of endothelial activation; in vivo, agents that augment endothelial NF-kappa-B and raise ICAM-1/VCAM-1 accelerated atherosclerosis in apoE-knockout mice. A published controversy that must travel with this edge — A journal of clinical investigation perspective is titled 'NF-kappa-B: pivotal mediator OR innocent bystander in atherogenesis?' The causal-versus-correlative question was posed in the title of a major review and is not closed. The adhesion molecules ARE not interchangeable: knockout work found a major role for VCAM-1 but not ICAM-1 in early atherosclerosis (J Clin Invest 2001;107:1255-1262), while P-selectin or ICAM-1 deficiency substantially protected apoE-deficient mice. And VCAM-1 expression MIGRATES as disease progresses — predominating in endothelial cells in early lesions and shifting to intimal cells later. Stage decides which molecule matters. PMC5857062

It increases Joint wear.

NF-κB has long been recognized as a disease-contributing factor in osteoarthritis and is an established therapeutic target: mechanical stress together with synovial inflammation drives NF-κB-dependent chondrocyte catabolism and degradation of the cartilage extracellular matrix (review, PMC6678954). Mechanism: under OA stimuli chondrocytes lose the ability to maintain cartilage integrity and convert to catabolic cells secreting matrix-degrading enzymes -- MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 -- with ADAMTS5 transcription driven by the NF-kappa-B family member RelA/p65. Loss-of-function confirms it: inhibiting NF-kappa-B activation significantly rescued expression of both the inflammatory cytokines and the cartilage-degradation enzymes in stimulated chondrocytes. the downstream proteases are not merely effectors -- MMPs and ADAMTS can propagate inflammatory signaling and amplify cartilage damage independently of cytokine activity, so blocking NF-kappa-B upstream does not necessarily stop them. PMC6678954